Company profile: Tetherex Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biotechnology therapeutics under development, including SelK2, a humanized monoclonal antibody targeting PSGL-1 for asthma and COPD, and SC-Ad6-1, a single-cycle adenovirus vector expressing the SARS-CoV-2 spike protein for intranasal or intramuscular administration to induce mucosal and systemic immunity against COVID-19.
Products and services
- SC-Ad6-1: Single-cycle adenovirus vector expressing the SARS-CoV-2 spike protein, architected for intranasal or intramuscular delivery to induce mucosal and systemic immunity against COVID-19
- SelK2: Humanized monoclonal antibody targeting PSGL-1, engineered for treating asthma and chronic obstructive pulmonary disease (COPD) with disease-specific application and under active development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tetherex Pharmaceuticals
Alder BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions leveraging proprietary technologies to accelerate antibody discovery and development. The company identifies, develops, produces, and markets its own antibody therapeutics aimed at generating better and safer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alder BioPharmaceuticals company profile →
iTeos Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology drug discovery and development focused on tumor immunology and the metabolism of the tumor microenvironment, delivering small molecule immunomodulators and antibody therapies for cancer. Portfolio includes EOS-448 (anti-TIGIT IgG1), Inupadenant (A2AR inhibitor), and EOS-984 (preclinical). Conducts clinical trials and advances monotherapy and combination therapy approaches across cancer indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iTeos Therapeutics company profile →
Celldex Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage antibody-based therapeutics, including monoclonal and bispecific antibodies, targeting inflammatory, allergic, autoimmune, and other severe diseases. Pipeline includes barzolvolimab (KIT inhibitor for mast cell-driven diseases) and CDX-585 (PD-1/ILT4 bispecific for solid tumors). Services include conducting clinical trials and offering compassionate use/expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celldex Therapeutics company profile →
Hawaii Biotech
HQ: United States
Website
- Description: Provider of biotechnology solutions focused on R&D of prophylactic vaccines for infectious diseases, including recombinant subunit vaccines (dengue, West Nile, Zika, tick-borne flaviviruses), viral hemorrhagic fevers (Crimean-Congo), and coronaviruses (SARS-CoV-2, pan-beta). Offers the GPI-0100 adjuvant, a protein production platform for vaccine development, and small molecule therapeutics for anthrax intoxication and botulism (BoNT type A).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hawaii Biotech company profile →
ADC Therapeutics
HQ: Switzerland
Website
- Description: Provider of targeted oncology therapies, developing antibody-drug conjugates and non-ADC products for hematological cancers and solid tumors using proprietary PBD-dimer technology. Offerings include ZYNLONTA (CD19 ADC), the LOTIS clinical trial program, ADCT-602 (CD22 ADC for acute lymphoblastic leukemia), Mipasetamab uzoptirine/ADCT-601 (AXL-targeting), PBD-dimer technology, and support for investigator-initiated trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tetherex Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tetherex Pharmaceuticals
2.2 - Growth funds investing in similar companies to Tetherex Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tetherex Pharmaceuticals
4.2 - Public trading comparable groups for Tetherex Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →